Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Express Scripts

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Details for Patent: RE33994

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: RE33994
Title: Pharmaceutical delivery system
Abstract:A composition for use in an aqueous environment which .[.comprise.]. .Iadd.comprises .Iaddend.a formulation containing a water-soluble pharmaceutically beneficial agent, a water-insoluble, water-permeable film coating surrounding the formulation, and particulate, water-soluble, pore-forming material dispersed within the film coating. The questions raised in reexamination request No. 90/001,344, filed Oct. 5, 1987, have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e).
Inventor(s): Baker; Richard W. (Palo Alto, CA), Brooke; James W. (Sisters, OR)
Assignee: Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:07/390,518
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent RE33994
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Drugs Protected by US Patent RE33994

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE33994

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8322007Aug 16, 1983

International Family Members for US Patent RE33994

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 1239034   Start Trial
Canada 1321754   Start Trial
Germany 10075031   Start Trial
Germany 3485618   Start Trial
Germany 3486409   Start Trial
European Patent Office 0171457   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.